---
document_datetime: 2024-12-16 15:29:03
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pemetrexed-pfizer-previously-pemetrexed-hospira-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: pemetrexed-pfizer-previously-pemetrexed-hospira-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.3857326
conversion_datetime: 2025-12-22 13:54:16.230973
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pemetrexed Pfizer

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0035               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                       | 13/12/2024                          |                                             | PL                               |           |
| IB/0034              | B.III.1.a.5 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate of a | 07/10/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | non-sterile AS that is to be used in a sterile medicinal product, where water is used in the last steps of the synthesis and the material is not claimed to be endotoxin free                                                                                                                                                                                                                                                                                                                                                            |            |            |                                  |                                                                                                                                                                                                                                                                                                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0033/G | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by       | 29/08/2022 | 04/08/2023 | SmPC, Annex II, Labelling and PL | C.I.2.a - To update Sections 4.4 and 4.6 of the SmPC based on the recommended wording provided in the 'Report from the CMD(h) meeting held on 20-21 July 2021' concerning duration of contraception following the end of treatment with a genotoxic drug. The PL has been updated accordingly. |
| IB/0030/G | This was an application for a group of variations. B.III.z - Quality Change - CEP/TSE/Monographs - Other variation B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch | 01/07/2022 | n/a        |                                  |                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|           | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other   |            |            |    | size variation   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|------------------|
| IB/0032   | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                          | 13/06/2022 | n/a        |    |                  |
| IB/0031/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS                                                                                            | 12/05/2022 | n/a        |    |                  |
| N/0029    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                 | 03/03/2022 | 04/08/2023 | PL |                  |
| N/0028    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                 | 14/09/2021 | 31/01/2022 | PL |                  |

<div style=\"page-break-after: always\"></div>

| IB/0027     | - Change in the manufacturing process of finished or intermediate product - Minor change the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                    | 08/04/2021   | n/a        |                        | B.II.b.3.a the in                        |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------------------------|
| IAIN/0026/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing change - Deletion of | 08/02/2021   | 31/01/2022 | Annex II and PL        | A.7 - Administrative manufacturing sites |
| X/0021      | Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                                              | 23/07/2020   | 30/09/2020 | SmPC, Labelling and PL |                                          |
| IB/0025     | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                                                                                             | 24/09/2020   | n/a        |                        |                                          |
| II/0024     | B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                    | 24/09/2020   | n/a        |                        |                                          |

<div style=\"page-break-after: always\"></div>

|           | manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                                  |                                                                                                                                                                                                                                                                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0022    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/06/2020 | 10/08/2020 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Pemetrexed Hospira in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0023/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                         | 24/06/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                  |
| II/0020/G | This was an application for a group of variations. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 16/01/2020 | 12/05/2020 | Annex II and PL                  |                                                                                                                                                                                                                                                                                  |
| IB/0019   | C.I.2.a - Change in the SPC, Labelling or PL of a                                                                                                                                                                                                                                                                                                                                                                                                            | 28/05/2019 | 12/05/2020 | SmPC and PL                      |                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| N/0018    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                             | 12/04/2019 | 12/05/2020 | PL                     |
| IA/0017   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                | 18/03/2019 | n/a        |                        |
| IA/0016   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                | 19/12/2018 | n/a        |                        |
| N/0015    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                             | 31/10/2018 | 12/05/2020 | PL                     |
| T/0014    | Transfer of Marketing Authorisation                                                                                                                                                                          | 06/08/2018 | 18/10/2018 | SmPC, Labelling and PL |
| IAIN/0013 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                               | 24/04/2018 | 18/10/2018 | SmPC and PL            |
| IA/0012   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)             | 28/02/2018 | n/a        |                        |
| N/0011    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                             | 20/11/2017 | 08/05/2018 | PL                     |

<div style=\"page-break-after: always\"></div>

| IB/0010   | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                               | 15/09/2017   | n/a        |                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|
| IB/0009   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 11/05/2017   | 08/05/2018 | SmPC, Labelling and PL |
| N/0008    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 16/02/2017   | 08/05/2018 | Labelling and PL       |
| IA/0007   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                | 03/02/2017   | n/a        |                        |
| IB/0006   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                | 14/01/2017   | n/a        |                        |
| IAIN/0005 | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                    | 08/07/2016   | n/a        |                        |
| N/0004    | Update of the package leaflet with revised contact details of the local representatives for Belgium, Germany, Spain, Ireland, Luxembourg, the Netherlands, Austria and Portugal.                                                                             | 17/06/2016   | 08/05/2018 | PL                     |

<div style=\"page-break-after: always\"></div>

|         | change in labelling or package leaflet not with the SPC (Art. 61.3 Notification)                                                                                |            |     | Minor connected   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| IG/0693 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                              | 02/06/2016 | n/a |                   |
| IA/0002 | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                    | 25/02/2016 | n/a |                   |
| IG/0645 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location | 17/12/2015 | n/a |                   |